Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Encompass Health Corp has a consensus price target of $86.69 based on the ratings of 16 analysts. The high is $110 issued by UBS on September 25, 2024. The low is $57 issued by Barclays on March 14, 2023. The 3 most-recent analyst ratings were released by UBS, Truist Securities, and UBS on September 25, 2024, August 15, 2024, and August 8, 2024, respectively. With an average price target of $104.67 between UBS, Truist Securities, and UBS, there's an implied 8.18% upside for Encompass Health Corp from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Encompass Health (NYSE:EHC) was reported by UBS on September 25, 2024. The analyst firm set a price target for $110.00 expecting EHC to rise to within 12 months (a possible 13.70% upside). 20 analyst firms have reported ratings in the last year.
The latest analyst rating for Encompass Health (NYSE:EHC) was provided by UBS, and Encompass Health maintained their buy rating.
There is no last upgrade for Encompass Health
There is no last downgrade for Encompass Health.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Encompass Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Encompass Health was filed on September 25, 2024 so you should expect the next rating to be made available sometime around September 25, 2025.
While ratings are subjective and will change, the latest Encompass Health (EHC) rating was a maintained with a price target of $100.00 to $110.00. The current price Encompass Health (EHC) is trading at is $96.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.